Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.220
-0.190 (-4.31%)
At close: Apr 28, 2026, 4:00 PM EDT
4.220
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$107,205
Profits / Employee
-$889,356
Market Cap
586.56M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Absci | 140 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| Prothena Corporation | 67 |
| Zevra Therapeutics | 61 |
ACRS News
- 8 hours ago - Aclaris Therapeutics Transcript: Study update - Transcripts
- 10 hours ago - Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor - GlobeNewsWire
- 1 day ago - Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - GlobeNewsWire
- 14 days ago - Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Transcripts
- 20 days ago - Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - GlobeNewsWire
- 4 weeks ago - Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewsWire